Investigation Report on China Bevacizumab Market ,2010-2019
|発行||China Research and Intelligence||商品コード||296861|
|出版日||ページ情報||英文 20 Pages
|中国のベバシズマブ市場の分析 Investigation Report on China Bevacizumab Market ,2010-2019|
|出版日: 2015年07月24日||ページ情報: 英文 20 Pages||
Colon cancer is a common gastrointestinal tumor whose incidence varies greatly in different countries. In developed countries, colon cancer is only second to lung cancer among malignant cancers. Its incidence decreases every year in the US and the EU but increases remarkably during the past four decades in Japan. According to the statistics published by the Ministry of Health of the People's Republic of China in 2011, 92-170 out of 1 million people suffer from colon cancer, sex ratio for which is 1.2:1. Although the incidence of colon cancer in China is higher than that in developed countries, it has decreased slightly in recent years.
Developed by Roche under the trade name of Avastin, bevacizumab injection is the first angiogenesis inhibitor in the world. In Feb.26, 2010, it was approved by CFDA to treat metastatic colorectal cancer. Currently, bevacizumab injections available in China all come from Roche and its subsidiary Genectech. In Jul. 2013, Kanion Pharmaceutical's Establishment of Evaluation System of Traditional Chinese Medicine's Efficacy in Treating Gastrointestinal Inflammatory Disease as well as Jiangsu Hengrui Medicine Co., Ltd's Introduction of Monoclonal Antibody Technology and Development of Bevacizumab have been designated by the Ministry of Science and Technology of the People's Republic of China as Key International S&T Cooperation Projects. In Dec. 2013, phase I clinical trial of the generic drug of bevacizumab co-developed by Huahai Pharmaceutical and Oncobiologics was approved to be conducted in the EU.
Bevacizumab injection develops fast after entering China, sales value reaching CNY 265 million in 2013 despite a slight decline in 2014 and CAGR during the period of 2010-2014 reaching 126.67%. With improvements in living standards and lifestyle changes, obesity rate in China goes up gradually, which increases the risk of colorectal cancer. Hence the vast demand for bevacizumab injection in China. Currently, the market is monopolized by Shanghai Roche Pharmaceutical Co., Ltd that brought in a sales value of CNY 264 million in 2014. As some local enterprises are trying to make generic drugs of bevacizumab injection, the monopoly of Roche is expected to be broken by local products in the next few years.
Readers can get at least the following information from this report:
The author suggests the following groups of people purchase this report: